Premium
P1‐006: Incorporation of resveratrol into lipid‐core nanocapsules improves its cerebral bioavailability and reduces the Aβ‐induced toxicity
Author(s) -
Frozza Rudimar L.,
Salbego Christianne,
Bernardi Andressa,
Hoppe Juliana Bender,
Meneghetti André,
Battastini Ana Maria,
Guterres Sílvia,
Pohlmann Adriana
Publication year - 2011
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2011.05.286
Subject(s) - resveratrol , nanocapsules , bioavailability , chemistry , pharmacology , dispersity , zeta potential , chromatography , nanoparticle , biochemistry , materials science , nanotechnology , medicine , organic chemistry
vitro, BQCA increased carbachol potency approx. 90-fold at 10 ÂmM (n 1⁄4 6). In vivo, a maximal brain level of 270 nM was observed 40 min after i.p. administration at 10 mg/kg. Based on in vitro experiments, at level BQCA should produce about 3-fold increase of the agonist potency; it reduced a scopolamine-induced hyper locomotion. Further, BQCA reversed a deficit observed in the two models of memory impairment. Moreover, BQCA showed no side effect at 10 mg/kg and above in spontaneous locomotion as well as in the salivation test. Conclusions: Altogether, these data suggest that theM1 PAMBQCAmay be of interest for the treatment of memory deficits observed in Alzheimer’s disease.